These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 37113064)

  • 1. Comparison of circulating tumor DNA between African American and Caucasian patients with metastatic castrate-resistant prostate cancer post-abiraterone and/or enzalutamide.
    Jang A; Lanka SM; Huang M; Casado CV; Caputo SA; Sweeney PL; Gupta K; Pocha O; Habibian N; Hawkins ME; Lieberman AD; Schwartz J; Jaeger EB; Miller PJ; Layton JL; Barata PC; Lewis BE; Ledet EM; Sartor O
    Prostate; 2023 Aug; 83(11):1028-1034. PubMed ID: 37113064
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes Among African American and Non-Hispanic White Men With Metastatic Castration-Resistant Prostate Cancer With First-Line Abiraterone.
    Marar M; Long Q; Mamtani R; Narayan V; Vapiwala N; Parikh RB
    JAMA Netw Open; 2022 Jan; 5(1):e2142093. PubMed ID: 34985518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt-pathway Activating Mutations Are Associated with Resistance to First-line Abiraterone and Enzalutamide in Castration-resistant Prostate Cancer.
    Isaacsson Velho P; Fu W; Wang H; Mirkheshti N; Qazi F; Lima FAS; Shaukat F; Carducci MA; Denmeade SR; Paller CJ; Markowski MC; Marshall CH; Eisenberger MA; Antonarakis ES
    Eur Urol; 2020 Jan; 77(1):14-21. PubMed ID: 31176623
    [TBL] [Abstract][Full Text] [Related]  

  • 4. TP53 Gain-of-Function Mutations in Circulating Tumor DNA in Men With Metastatic Castration-Resistant Prostate Cancer.
    Chapman L; Ledet EM; Barata PC; Cotogno P; Manogue C; Moses M; Christensen BR; Steinwald P; Ranasinghe L; Layton JL; Lewis BE; Sartor O
    Clin Genitourin Cancer; 2020 Apr; 18(2):148-154. PubMed ID: 31822380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
    Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
    Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.
    Moses M; Niu A; Lilly MB; Hahn AW; Nussenzveig R; Ledet E; Manogue C; Cotogno P; Lewis B; Layton J; Agarwal N; Sartor O; Barata PC
    Cancer Treat Res Commun; 2020; 24():100193. PubMed ID: 32702615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.
    Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Nakazawa M; Nadal R; Paller CJ; Denmeade SR; Carducci MA; Eisenberger MA; Luo J
    JAMA Oncol; 2015 Aug; 1(5):582-91. PubMed ID: 26181238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide.
    Antonarakis ES; Lu C; Luber B; Liang C; Wang H; Chen Y; Silberstein JL; Piana D; Lai Z; Chen Y; Isaacs WB; Luo J
    Eur Urol; 2018 Aug; 74(2):218-225. PubMed ID: 29439820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical activity of enzalutamide versus docetaxel in men with castration-resistant prostate cancer progressing after abiraterone.
    Suzman DL; Luber B; Schweizer MT; Nadal R; Antonarakis ES
    Prostate; 2014 Sep; 74(13):1278-85. PubMed ID: 25053178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overall and progression-free survival of Afro-Caribbean men with metastatic castration-resistant prostate cancer (mCRPC).
    Vestris PG; Gourtaud G; Senechal C; Sadreux Y; Roux V; Blanchet P; Brureau L
    Prostate; 2022 Feb; 82(2):269-275. PubMed ID: 34822183
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment Outcomes and Tumor Loss of Heterozygosity in Germline DNA Repair-deficient Prostate Cancer.
    Annala M; Struss WJ; Warner EW; Beja K; Vandekerkhove G; Wong A; Khalaf D; Seppälä IL; So A; Lo G; Aggarwal R; Small EJ; Nykter M; Gleave ME; Chi KN; Wyatt AW
    Eur Urol; 2017 Jul; 72(1):34-42. PubMed ID: 28259476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
    Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
    Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential treatment outcomes in BRCA1/2-, CDK12-, and ATM-mutated metastatic castration-resistant prostate cancer.
    Kwon DH; Chou J; Yip SM; Reimers MA; Zhang L; Wright F; Dhawan MS; Borno HT; Desai A; Aggarwal RR; Wyatt AW; Small EJ; Alva AS; Chi KN; Feng FY; Koshkin VS
    Cancer; 2021 Jun; 127(12):1965-1973. PubMed ID: 33690902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases.
    Schoen MW; Carson KR; Eisen SA; Bennett CL; Luo S; Reimers MA; Knoche EM; Whitmer AL; Yan Y; Drake BF; Sanfilippo KM
    Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):743-750. PubMed ID: 36104504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Use of Circulating Tumor DNA for the Clinical Management of Metastatic Castration-Resistant Prostate Cancer: A Multicenter, Real-World Study.
    Dong B; Fan L; Yang B; Chen W; Li Y; Wu K; Zhang F; Dong H; Cheng H; Pan J; Zhu Y; Chi C; Dong L; Sha J; Li L; Yao X; Xue W
    J Natl Compr Canc Netw; 2021 May; 19(8):905-914. PubMed ID: 33990090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study.
    Sternberg CN; Castellano D; de Bono J; Fizazi K; Tombal B; Wülfing C; Kramer G; Eymard JC; Bamias A; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; de Wit R
    Eur Urol; 2021 Oct; 80(4):497-506. PubMed ID: 34274136
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer.
    Tolmeijer SH; Boerrigter E; Sumiyoshi T; Kwan EM; Ng SWS; Annala M; Donnellan G; Herberts C; Benoist GE; Hamberg P; Somford DM; van Oort IM; Schalken JA; Mehra N; van Erp NP; Wyatt AW
    Clin Cancer Res; 2023 Aug; 29(15):2835-2844. PubMed ID: 36996325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AR-V7 in circulating tumor cells cluster as a predictive biomarker of abiraterone acetate and enzalutamide treatment in castration-resistant prostate cancer patients.
    Okegawa T; Ninomiya N; Masuda K; Nakamura Y; Tambo M; Nutahara K
    Prostate; 2018 Jun; 78(8):576-582. PubMed ID: 29508425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.
    Kohli M; Tan W; Zheng T; Wang A; Montesinos C; Wong C; Du P; Jia S; Yadav S; Horvath LG; Mahon KL; Kwan EM; Fettke H; Yu J; Azad AA
    EBioMedicine; 2020 Apr; 54():102728. PubMed ID: 32268276
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Third-line Enzalutamide Following Docetaxel and Abiraterone in Metastatic Castrate-resistant Prostate Cancer.
    Davies RS; Smith C; Lester JF
    Anticancer Res; 2016 Apr; 36(4):1799-803. PubMed ID: 27069162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.